Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDX105 for prevention of regorafenib-induced dermatologic toxicity in colorectal cancer
ChiCTR2200057154Phase 3Not yet recruiting
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Feb 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of Fufang Danxiong Granules in dermatologic toxicity and Hand-foot skin reaction (HFSR) (2 arms), sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Incidence of grade 3 hand-foot skin reaction. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
Fufang Danxiong Granules
03
Conditions
dermatologic toxicityHand-foot skin reaction (HFSR)
Beyond the preview
Go deeper on ChiCTR2200057154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057154.